Sanjay MBA - Zenith Capital Chief Officer

All Insiders . USA . 
Stock . Zenith Capital Corp . Stakeholders . Insider . Sanjay MBA
ZHCLF Stock  USD 0.11  0.01  10.00%   

Insider

Sanjay MBA is Chief Officer of Zenith Capital Corp
Webhttps://www.zenithepigenetics.com

Zenith Capital Management Efficiency

The company has return on total asset (ROA) of (1.6034) % which means that it has lost $1.6034 on every $100 spent on assets. This is way below average. Zenith Capital's management efficiency ratios could be used to measure how well Zenith Capital manages its routine affairs as well as how well it operates its assets and liabilities.
Zenith Capital Corp has accumulated 3.94 M in total debt. Zenith Capital Corp has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Zenith Capital until it has trouble settling it off, either with new capital or with free cash flow. So, Zenith Capital's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zenith Capital Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zenith to invest in growth at high rates of return. When we think about Zenith Capital's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gina MazzarielloAmylyx Pharmaceuticals
53
Shauna HorvathAmylyx Pharmaceuticals
N/A
Robert MBAEliem Therapeutics
56
Tom HolmesAmylyx Pharmaceuticals
N/A
Kyung NamWortmanCellectis SA
53
Gerry ArambulaCovalon Technologies
N/A
Elaine ZhangCovalon Technologies
N/A
CPA CPAArvinas
52
Brian SullivanCelcuity LLC
62
Esq JDIovance Biotherapeutics
48
Vicky HahneCelcuity LLC
58
MD MBAPortage Biotech
56
Jean EpinatCellectis SA
N/A
Simon SmithCovalon Technologies
N/A
Mark LappeInhibrx
57
Susan MSEliem Therapeutics
N/A
Dennis ChenProMIS Neurosciences
N/A
BS CPAInhibrx
42
Brian WileyPortage Biotech
56
Sheri SmithCelcuity LLC
N/A
Igor BilinskyIovance Biotherapeutics
51
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company was incorporated in 2013 and is headquartered in Calgary, Canada. Zenith Cap operates under Biotechnology classification in the United States and is traded on OTC Exchange. Zenith Capital Corp [ZHCLF] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

Return On Asset-1.6

Zenith Capital Corp Leadership Team

Elected by the shareholders, the Zenith Capital's board of directors comprises two types of representatives: Zenith Capital inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zenith. The board's role is to monitor Zenith Capital's management team and ensure that shareholders' interests are well served. Zenith Capital's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zenith Capital's outside directors are responsible for providing unbiased perspectives on the board's policies.
Donald McCaffrey, Pres Chairman
Huan Zhu, Chief Officer
Henrik Hansen, VP Operations
Sanjay MBA, Chief Officer

Zenith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Zenith Capital a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-1.6
Current Valuation23.33 M
EBITDA(7.31 M)
Net Income(7.8 M)
Cash And Equivalents19 K
Total Debt3.94 M
Current Ratio0.17 X
Book Value Per Share(0.10) X
Cash Flow From Operations(847 K)
Earnings Per Share(0.06) X

Currently Active Assets on Macroaxis

ESRTEmpire State Realty
CCitigroup
CCitigroup
GOOGAlphabet Inc Class C
DDDupont De Nemours

Other Information on Investing in Zenith Pink Sheet

Zenith Capital financial ratios help investors to determine whether Zenith Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenith with respect to the benefits of owning Zenith Capital security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY